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248 Liver function and vitamin D in children with cystic ﬁbrosis
M.F. Roddy1,2, B. Elnazir2, P. Greally2. 1The National Childrens Hospital,
Dietetics, Dublin, Ireland; 2AMNCH, Cystic Fibrosis Department, Dublin, Ireland
Introduction: The liver is important in the metabolism of vitamin D especially its
hydroxylation to 25OHD3. Liver disease occurs in up to 15−20% of children with
CF raising the possibility that Vitamin D levels may be inﬂuenced by their liver
function. Our aim was to look at vitamin D levels in children and to correlate it
with their liver function tests.
Methods: A retrospective review of Vitamin D levels and liver function tests (AST,
ALT, GGT, Alk Phos, Protein and Albumin) was conducted. Seventy-seven children
with mean age of 12 were included in study. Minitab Statistical Package was used
to analyse the data. Regression analysis and independent t tests were carried out to
determine any relationship between vitamin D and liver function.
Results: Eleven children (14%) had a diagnosis of CF related liver disease (CFLD).
The mean vitamin D was 73.12 (±28 SD) with no difference in mean vitamin D
between CFLD patients and none CFLD patients (mean of 65 nmol/ L versus
75 nmol/ L respectively, p = 0.27). Vitamin D negatively correlated with GGT,
protein and ALT (p = 0.02, 0.04 and 0.02 respectively). Vitamin D did not correlate
with albumin, AST or Alk Phos (p = 0.93, 0.68 and 0.56 respectively). When those
with CFLD were removed from the data, vitamin D still negatively correlated with
protein (p = 0.04) and GGT (p = 0.03).
Conclusion: The cause of low vitamin D in CF is multifactorial. This study provides
some evidence of a direct relationship (either cause or effect) between vitamin D
and liver function. Further research is needed to determine if increased vitamin D
supplementation in CF would affect liver function.
249 Inﬂuence of calcium and vitamin D on bone mineral density in
children with cystic ﬁbrosis
T. Jakovska-Maretti1, S. Fustik1, L. Spirevska1. 1University Pediatric Clinic, CF
Center, Skopje, Macedonia, the Former Yugoslav Republic of
Low bone mineral density (BMD) is relatively frequent ﬁnding among patients with
cystic ﬁbrosis (CF). This complication is related with age, severity of lung damage
and nutrition disorders.
Aim: To evaluate the effect of calcium and vitamin D supplementation on low
BMD in patients with CF.
Materials and Methods: Z-score of BMD was assessed in 47 patients with CF
and was performed with Quantitative Ultrasound. Chest deformation was found in
1/3 of schoolchildren with CF. Children with CF were divided into two groups:
ﬁrst group: 26 children younger than 12 years; second group: 21 children older
than 12 years. All patients were pancreatic insufﬁcient and received adequate basic
therapy including multivitamins. Calcium and vitamin D supplements were given
to correct the low values of BMD in children with CF for six months.
Results: Initial Z-score showed decreased values in both study groups:
−0.14±1.17 SD in CF children <12 years and −1.29±0.9 SD in CF patients
>12 years. 25OHD values in the younger group were 29.3±15.2 ng/ml and
18.07±8.3 ng/ml in older group. Calcium values were similar in the two groups
(2.4±0.1; 2.37±0.2). After six months of treatment with calcium and vitamin D
supplementation, the control densitometry showed signiﬁcant increase in Z-score
to 0.9±1.5 SD in children <12 years and to −0.9±1.1 SD in older CF patients.
Conclusion: Calcium and vitamin D have positive effect on mineral bone density
in children with CF.
250 Vitamin D deﬁciency and thoracic kyphosis in adult cystic
ﬁbrosis patients
L. O’Shaughnessy1, C. Reilly2, E. Caples3, E. McKone4, C. Gallagher4.
1St. Vincents University Hospital, Dietetics, Dublin, Ireland; 2St Vincent’s
University Hospital, Department of Physiotherapy, Dublin, Ireland; 3St Vincent’s
University Hospital, Department of Nutrition and Dietetics, Dublin, Ireland;
4St Vincent’s University Hospital, National Referral Centre for Adult Cystic
Fibrosis, Dublin, Ireland
Objectives: This study tested the hypothesis that there is an association between
vitamin D deﬁciency and thoracic kyphosis in adults with Cystic Fibrosis (CF).
Methods: Subjects were recruited during annual review at the National Referral
Centre for Adult Cystic Fibrosis. Each subject had thoracic curvature measured
using a ﬂexible ruler (previously validated against lateral x-ray), and had venous
blood sampling to measure vitamin D level.
Results: 36 patients were included in the study, M:F ratio = 1.64:1.
5.5% of patients were in the severe lung disease category while 44% and 50%
had moderate and mild disease respectively. 40.5% of patients were kyphotic
(thoracic curvature greater than 40º). 13.8% of patients had optimal vitamin D levels
(>75 nmol/L) and 2.7% were severely deﬁcient with a measurement <25 nmol/L.
A weak correlation of r = 0.17 was found between angle of kyphosis and vitamin D
levels. 43% of those patients studied had exposure to oral steroids.
Conclusions: The prevalence of vitamin D deﬁciency in this population was very
high. But only weak correlation was found between the angle of thoracic kyphosis
and vitamin D level. Further investigation would be of beneﬁt to look at bone
density and nutritional status in this population.
251 Should %ideal body weight (%IBW) or body mass index
percentile (BMIp) be used to assess growth in children with
cystic ﬁbrosis?
K. Maslin1, T. Curbishley1, H. Kay2, J. Legg2. 1University Hospital Southampton,
Nutrition and Dietetics, Southampton, United Kingdom; 2University Hospital
Southampton, Paediatric Respiratory Unit, Southampton, United Kingdom
Background: There is strong evidence that BMIp predicts nutritional failure more
sensitively and accurately than %IBW, having a stronger correlation with %FEV1.
This study aims to determine which growth measurement correlates most closely
with %FEV1 in a UK population. Studies comparing both methods have concluded
there is little difference for children of average height, but in short and tall children,
underweight can be misclassiﬁed. %IBW is the main growth outcome measure in
the 2002 CF Trust guidelines, which are currently under review.
Methods: Data was obtained from the 2010 South & South West regional CF
database. Height, weight, BMIp and %FEV1 were calculated at annual review.
BMIp was converted to Standard Deviation Scores (SDS) using UK reference data.
Results: Data was collected from 263 children (age range 5−17 years). Me-
dian %IBW was 101 (SD ±16.17, range 67–198). BMI SDS range was −3.21
to 3.57 (median −0.08±1.13). Median %FEV1 was 87 (SD ±19.8, range 28–129).
Overall, both %IBW and BMI SDS had a signiﬁcant association with %FEV1,
with BMI SDS having a stronger correlation (r = 0.3, p< 0.01). In children between
5−12 years old (n = 115), the association between BMI SDS and %FEV1 was weaker
(r = 0.18, p< 0.05), with no signiﬁcant association between %IBW and %FEV1. In
children with height >75th percentile (n = 43), neither growth measurement was
signiﬁcantly associated with %FEV1.
Conclusion: Compared to %IBW, BMIp is more closely associated with lung func-
tion in children <75th percentile for height. The lack of correlation with either
growth measurement and %FEV1 in tall children raises the possibility that other
growth measures should be employed in this group.
